TNF Type-I Receptor Inhibitor, R-7050 Attenuates Acute Kidney Injury in a Mouse Model of Crush Syndrome - Pharmacology & Pharmacy

PP > Vol.9 No.12, December 2018

TNF Type-I Receptor Inhibitor, R-7050 Attenuates Acute Kidney Injury in a Mouse Model of Crush Syndrome ()

HTML XML

Download as PDF (Size: 786KB) PP. 547-558

DOI: 10.4236/pp.2018.912043 848 Downloads 1,908 Views

Author(s)

Shinya Mizuno^1,2,3, Eriko Osaki², Hiroyuki Ohnishi^1,4

Affiliation(s)

¹Department of Biochemistry and Molecular Biology in Osaka University Graduate School of Medicine, Suita, Japan.
²Department of Microbiology and Immunology in Osaka University Graduate School of Medicine, Suita, Japan.
³Department of Zoology, Okayama University of Science (RIDAI), Okayama, Japan.
⁴Kitasato University School of Allied Health Science, Sagamihara, Japan.

ABSTRACT

Crush syndrome (CS) is caused by severe and extensive muscular skeletal damages, and acute kidney injury (AKI) with hyperkalemia is one of the most lethal factors of this syndrome. Especially under natural disasters of earthquake, many persons die due to AKI and hyperkalemia-induced cardiac arrest, but there has been no pathogenesis-based drugs for preventing CS-induced AKI. Pro-inflammatory cytokines, such as TNF-α and IL-6, play a critical role for induction of AKI during CS development. Glycerol-injected mice are used as an experimental tool for reflecting pathological events of human CS. Using this popular model, we provide evidence to show that TNF type-I receptor (TNFR1) inhibitor, R-7050 significantly attenuates the onset of AKI after the muscular destruction. In this process, R-7050 treatment suppressed the NF-κB activation in the affected kidney, and this was associated with a decrease in blood IL-6, a downstream target of NF-κB. As a result, renal tubular apoptosis became milder in the R-7050-treated CS mice. These findings suggest that induction of IL-6 via sequential events of TNF-α à TNFR1 à NF-κB is contributable for renal tubular apoptosis, a histological hallmark of AKI. Thus, TNFR1-selective inhibition can be a pharmacological strategy to attenuate the onset of AKI immediately after the clinical manifestation of rhabdomyolysis.

KEYWORDS

AKI, Hyperkalemia, IL-6, Rhabdomyolysis, TNF-α

Share and Cite:

Mizuno, S. , Osaki, E. and Ohnishi, H. (2018) TNF Type-I Receptor Inhibitor, R-7050 Attenuates Acute Kidney Injury in a Mouse Model of Crush Syndrome. Pharmacology & Pharmacy, 9, 547-558. doi: 10.4236/pp.2018.912043.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies